Welcome to the Rana Lab
RNA and Chemical Biology approaches to develop new immunotherapies and cures for cancer and HIV/AIDS
We are a multidisciplinary laboratory focused on discovering fundamental mechanisms of RNA biology that regulate immune response to viral infections and cancer, and the host response to immunotherapy. Our team has helped to uncover numerous functions of regulatory RNA assemblies in gene silencing, stem cell biology, cancer, immunity, and host-pathogen interactions.
Dr. Tariq Rana is a scholar, inventor, entrepreneur, and multidisciplinary scientist who is developing new therapies to treat infectious disease, cancer, and immune disorders. He is a Professor and Head of Genetics, V/C for Innovation in Therapeutics, Department of Pediatrics at the University of California San Diego School of Medicine, where his laboratory employs mechanisms and technologies of RNA, stem cells, and chemical biology to discover new pathways implicated in human disease.
Using genetic sequencing, University of California San Diego School of Medicine researchers have identified a principal cellular player controlling HIV reproduction in immune cells which, when turned off or deleted, eliminates dormant HIV reservoirs. UCSD Health News Sep 2019
Chronic infection with human immunodeficiency virus (HIV) can cause progressive loss of immune cell function, or exhaustion, which impairs control of virus replication. However, little is known about the development and maintenance, as well as heterogeneity of immune cell exhaustion. – BIORIXV, June 21, 2019
“Zika causes a fetus’s developing brain to essentially attack itself in a pregnancy, according to remarkable new research into the mosquito-borne virus. And there might be a way to stop it. As images of babies born with shrunken skulls continue to emerge from Zika-stricken countries, the research helps answer a persistent question of how, exactly, the virus arrests a baby’s development in utero” – Newsweek, May 2016
Cancers driven by mutations in the KRAS gene are among the most deadly. For decades, researchers have tried unsuccessfully to directly target mutant KRAS proteins as a means to treat tumors. Instead of targeting mutant KRAS itself, researchers at University of California San Diego School of Medicine are now looking for other genes or molecules that, when inhibited, kill cancer cells only when KRAS is also mutated. – UCSD Health Newsroom, September 27, 2017
“There are many genes and proteins being studied for their roles in inflammation and innate immunity, as well as for drug design,” said Tariq Rana, PhD, professor of pediatrics at UC San Diego School of Medicine. “Yet only two percent of the human genome actually encodes proteins.” – UCSD Health Sciences, March 27, 2019
See more of our featured articles and news.